TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Deadline Alert: MoonLake Immunotherapeutics (MLTX) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Glancy Prongay & Murray Llp
Deadline Alert: MoonLake Immunotherapeutics (MLTX) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

MoonLake Immunotherapeutics faces potential securities fraud lawsuit after announcing disappointing Phase 3 results for its drug candidate sonelokimab, which failed to match competitor's drug efficacy, causing significant stock price drop.

Insights
AMZN   positive

Stock increased by 4.78%, demonstrating significant market strength


MLTX   negative

Stock price dropped 89.9% after revealing drug candidate's lack of competitive advantage, potential misrepresentation of clinical trial results, and potential legal action by shareholders